Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × magrolimab × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3 Lymphoid 3 Head & Neck 2 Gastrointestinal 2 Sarcoma 1 Plasma cell 1 Other solid neoplasm 1 Gynecologic 1 CNS 1 Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Trastuzumab 222 Paclitaxel 189 Cyclophosphamide 151 Docetaxel 122 Letrozole 111 Capecitabine 111 Fulvestrant 104 Doxorubicin 97 Carboplatin 81 Bevacizumab 81 exemestane 75 Anastrozole 73 Lapatinib 69 Tamoxifen 66 Albumin-Bound Paclitaxel 58 Taxes 55 palbociclib 54 pembrolizumab 53 Gemcitabine 51 pertuzumab 47 eribulin 45 130-nm albumin-bound paclitaxel 40 Radiotherapy 37 Everolimus 37 Vinorelbine 36 Ado-Trastuzumab Emtansine 36 ixabepilone 32 pegfilgrastim 28 Magnetic Resonance Spectroscopy 27 Goserelin 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04958785 2025-11-04

ELEVATE TNBC

Gilead Sciences

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡